上海皓元医药股份有限公司 关于收到上海证券交易所《关于上海皓元医药股份有 限公司向不特定对象发行可转换公司债券申请文件 的第二轮审核问询函》的公告 证券代码：688131 证券简称：皓元医药 公告编号：2023-083 公司将与相关中介机构按照上述《二轮问询函》的要求，对相关问题进行逐 项落实，并及时提交对《二轮问询函》的回复，回复内容将通过临时公告方式及 时披露，并通过上交所发行上市审核业务系统报送相关文件。 公司本次向不特定对象发行可转换公司债券事项尚需通过上交所审核，并获 得中国证券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方 可实施，最终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间 尚存在不确定性。公司将根据该事项的进展情况，严格按照相关法律法规的要求 及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 1 上海皓元医药股份有限公司董事会 2023 年 8 月 19 日 2 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海皓元医药股份有限公司（以下简称"公司"）于 2 ...

1.关于本次募投项目 根据申报材料，1）"高端医药中间体及原料药 CDMO 产业 化项目（一期）"主要为创新药客户提供 CDMO 服务，随着公 1 上海证券交易所文件 上证科审（再融资）〔2023〕205 号 关于上海皓元医药股份有限公司向不特定 对象发行可转换公司债券申请文件 的第二轮审核问询函 上海皓元医药股份有限公司、民生证券股份有限公司： 根据《证券法》《上市公司证券发行注册管理办法》《上海 证券交易所上市公司证券发行上市审核规则》等有关法律、法规 及本所有关规定等，本所审核机构对上海皓元医药股份有限公司 （以下简称发行人或公司）向不特定对象发行可转换公司债券申 请文件，并形成了第二轮问询问题。 2 ─────────────── 司前端业务创新药研发客户的项目阶段逐步推进到临床试验阶 段，其对公司中间体以及原料药产生了更大的需求，倾向与公司 建立长期的 CDMO 合作关系；2）"安徽皓元药业有限公司年产 121.095 吨医药原料药及中间体建设项目（二期）"布局了 6 个 特色原料药及 1 个医药中间体产品，"265t/a 高端医药中间体产 品项目"拟新建项目布局 10 个医药中间体及 1 个原料药 ...

| 2.关于前次募投项目 | | 2 | | --- | --- | --- | | 3.关于融资规模和效益测算 | | 7 | | 4.关于经营业绩 | | 62 | | 5.关于存货 | | 114 | | 6.关于商誉 | | 142 | | 7.关于财务性投资 | | 158 | | 8.关于其他 | | 170 | | 8.1 | | 170 | 容诚会计师事务所(特殊普通合伙) 总所：北京市西城区阜成门外大街 22 号 外经贸大厦 15 层/922-926(10037) TEL: 010-6600 1391 FAX: 010-6600 1392 E-mail:bj@rsmchina.com.cn https//WWW.rsm.global/china/ 关于上海皓元医药股份有限公司 向不特定对象发行可转换公司债券申请文件 审核问询函的专项核查意见 容诚专字[2023]200Z0521 号 上海证券交易所： 贵所于 2023 年 6 月 5 日出具的《关于上海皓元医药股份有限公司向不特定对 象发行可转换公司债券申请文件的审核问询函》（上证科审（再融资）〔2023〕132 号）（以下简称"审核问询函" ...

关于上海皓元医药股份有限公司 向不特定对象发行可转换公司债券申请文件的 审核问询函的回复报告（修订稿） 保荐机构（主承销商） 二〇二三年八月 上海证券交易所： 贵所于 2023 年 6 月 5 日出具的《关于上海皓元医药股份有限公司向不特定 对象发行可转换公司债券申请文件的审核问询函》（上证科审（再融资）[2023]132 号）（以下简称"审核问询函"）已收悉。上海皓元医药股份有限公司（以下简 称"皓元医药"、"发行人"或"公司"）与民生证券股份有限公司（以下简称 "保荐机构"）、北京德恒律师事务所（以下简称"发行人律师"）、容诚会计 师事务所（特殊普通合伙）（以下简称"申报会计师"）等相关方已就审核问询 函中提到的问题逐项进行了认真讨论、核查和落实，现回复如下，请予审核。 说明： 1、如无特殊说明，本回复中使用的简称或名词释义与《上海皓元医药股份 有限公司向不特定对象发行可转换公司债券募集说明书（申报稿）》中的释义相 同。 2、本回复中若出现总计数位数与所列值总和不符的情况，均为四舍五入导 致。 3、为便于阅读，本回复不同内容字体如下： | 审核问询函所列问题 | 黑体（加粗） | | --- | --- ...

北京德恒律师事务所 关于 上海皓元医药股份有限公司 向不特定对象发行可转换公司债券的 补充法律意见书（一） 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 | 第一部分 | 律师声明事项 3 | | --- | --- | | 第二部分 | 对《首轮问询函》的回复 4 | | | 一、关于本次募投项目（《首轮问询函》问题 1） 4 | | | 二、关于前次募投项目（《首轮问询函》问题 2） 10 | | | 三、关于其他（《首轮问询函》问题 8.2） 15 | 北京德恒律师事务所 关于上海皓元医药股份有限公司 向不特定对象发行可转换公司债券的补充法律意见书（一） 北京德恒律师事务所 关于 上海皓元医药股份有限公司 向不特定对象发行可转换公司债券的 补充法律意见书（一） 德恒 02F20230015-00005 号 致：上海皓元医药股份有限公司 根据发行人与本所签订的《专项法律服务协议》，本所接受发行人委托担任 其本次向不特定对象发行可转换公司债券的专项法律顾问。本所已于 2023 年 5 月 24 日出具了德恒 02F ...

证券代码：688131 证券简称：皓元医药 公告编号：2023-049 上海皓元医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海皓元医药股份有限公司（以下简称"公司"）于 2023 年 3 月 22 日、4 月 28 日分别在上海证券交易所网站（www.sse.com.cn）发布公司 2022 年年度报告 及 2023 年第一季度报告。为便于广大投资者更全面深入地了解公司 2022 年年度 及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 5 月 16 日下午 13:00-14:30 举行 2022 年度暨 2023 年第一季度业绩暨现金分红说明会，就投资 者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频直播结合网络互动召开，公司将针对 2022 年年度 及 2023 年第一季度经营成果及财务指标的具体情况与投资者进行互动交流和沟 1 会议召开时间：2023 年 5 月 16 ...

Financial Performance - The company's total revenue for Q1 2023 reached RMB 418.37 million, representing a year-on-year increase of 39.46%[6] - The net profit attributable to shareholders decreased by 25.83% to RMB 46.24 million, while the net profit after deducting non-recurring gains and losses fell by 28.64% to RMB 41.96 million[6] - Total operating costs for Q1 2023 were ¥354,607,032.39, up 61.1% from ¥219,865,620.60 in Q1 2022[25] - Net profit for Q1 2023 was ¥46,068,348.53, a decrease of 25.5% from ¥61,771,891.90 in Q1 2022[26] - Operating profit for Q1 2023 was ¥47,936,796.00, down 29.3% from ¥67,898,249.96 in Q1 2022[25] - Basic earnings per share for Q1 2023 were ¥0.43, compared to ¥0.60 in Q1 2022[26] Research and Development - Research and development expenses totaled RMB 50.52 million, an increase of 50.95% year-on-year, accounting for 12.08% of total revenue[6] - Research and development expenses for Q1 2023 were ¥50,524,023.51, an increase of 50.9% from ¥33,470,762.57 in Q1 2022[25] - The company is actively enhancing its R&D capabilities with centers in multiple cities and is expanding its business operations internationally[12] - The company continues to focus on innovation and has implemented stock incentive plans for over 300 employees to support its strategic goals[13] - The company is focusing on technological innovation and industrial upgrades as part of its strategic initiatives[16] Assets and Liabilities - The company's total assets increased by 5.53% to RMB 3.80 billion compared to the end of the previous year[8] - The total current assets as of March 31, 2023, amounted to CNY 1,897,890,597.80, an increase from CNY 1,822,869,836.48 at the end of 2022, reflecting a growth of approximately 4.0%[19] - The total non-current assets as of March 31, 2023, were CNY 123,084,820.60, slightly up from CNY 75,590,454.31 at the end of 2022[19] - Total liabilities amounted to ¥1,408,819,244.19, up 11.3% from ¥1,265,778,968.40 in Q1 2022[21] Cash Flow - The company reported a significant increase in cash outflows from operating activities, primarily due to increased inventory purchases and higher employee compensation costs[11] - The net cash flow from operating activities was CNY -147,839,554.95, compared to CNY -3,784,513.39 in the same period last year[28] - The total cash outflow from operating activities was CNY 521,737,913.70, compared to CNY 262,392,414.67 in Q1 2022[28] - The total cash inflow from operating activities was CNY 373,898,358.75, an increase from CNY 258,607,901.28 in the same quarter last year[28] - The cash inflow from investment activities was CNY 341,445,562.65, significantly higher than CNY 47,474,574.57 in Q1 2022[29] - The cash inflow from financing activities was CNY 193,321,701.42, up from CNY 112,400,000.00 in Q1 2022[29] Shareholder Information - The top shareholder, Shanghai Anxu Information Technology Co., Ltd., holds 32.47% of the company's shares, totaling 34,736,166 shares[15] - The company reported a total of 7,674,660 shares held by the top shareholder, representing a significant portion of the total shares outstanding[16] - The company has a total of 1,989,724 shares held by China Industrial Bank, indicating strong institutional support[17] Workforce - The company expanded its workforce to 3,581 employees, an increase of 213 employees compared to the end of the previous year, primarily in production and technical roles[13] Other Information - The company has not reported any significant mergers or acquisitions during the quarter[18] - There are no significant changes in the company's financing or margin trading activities reported for this period[18] - Cash and cash equivalents decreased to CNY 304,569,982.51 from CNY 460,137,636.91, representing a decline of about 33.7%[19] - Inventory increased significantly to CNY 1,070,725,002.15, up from CNY 910,876,848.98, indicating a rise of approximately 17.6%[19] - Accounts receivable rose to CNY 407,502,261.10 from CNY 336,860,225.55, marking an increase of around 20.9%[19] - The ending balance of cash and cash equivalents was CNY 300,142,110.84, down from CNY 853,568,279.69 at the end of Q1 2022[29]

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 193,643,498.25 in 2022, with the parent company reporting a net profit of RMB 91,366,221.47[8]. - The company reported a significant increase in revenue, with a year-over-year growth of 25% in 2022[16]. - The company's operating revenue for 2022 was ¥1,358,053,975.22, representing a 40.12% increase compared to ¥969,225,559.54 in 2021[29]. - The net profit attributable to shareholders for 2022 was ¥193,643,498.25, a slight increase of 1.39% from ¥190,979,580.89 in 2021[29]. - The net cash flow from operating activities decreased significantly to -¥240,232,931.24, down 515.38% from ¥57,834,553.22 in 2021[29]. - The total assets at the end of 2022 reached ¥3,597,744,539.58, a 50.88% increase from ¥2,384,551,589.19 at the end of 2021[29]. - The company's net assets attributable to shareholders increased by 27.31% to ¥2,319,917,990.08 at the end of 2022, compared to ¥1,822,307,191.98 at the end of 2021[29]. - The basic earnings per share for 2022 was ¥1.86, a decrease of 11.43% from ¥2.10 in 2021[30]. - The company's gross profit margin was affected by rising operating costs, with operating costs increasing by 48.28% to CNY 659,411,057.33[168]. Dividend and Share Capital - The proposed cash dividend is RMB 3.80 per 10 shares, totaling RMB 40,653,263.36, which represents 20.99% of the annual net profit attributable to shareholders[8]. - The company plans to increase its total share capital by 42,792,908 shares through a capital reserve transfer, raising the total share capital to 149,775,180 shares[8]. - The company has a total of 106,982,272 shares as of March 20, 2023, which serves as the basis for dividend distribution and capital increase calculations[8]. Research and Development - The company is investing in R&D, with a budget increase of 30% for new drug development initiatives[18]. - The R&D expenditure as a percentage of operating revenue increased to 14.84% in 2022, up 4.17 percentage points from 10.67% in 2021[30]. - R&D investment reached 201.58 million yuan, a 94.85% increase compared to the previous year, accounting for 14.84% of total revenue[62]. - The company has developed over 5,900 types of recombinant proteins and antibodies, providing high-quality biological research reagents and technical services to global pharmaceutical R&D enterprises and life science research institutions[50]. - The company has developed a comprehensive service platform covering drug research and production, with approximately 7,000 global partners[68]. Market Expansion and Strategy - The company provided a positive outlook for 2023, projecting a revenue growth of 20%[18]. - Market expansion plans include entering three new international markets by the end of 2023[16]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting a deal valued at approximately $100 million[17]. - The company aims to increase its market share by 5% through enhanced marketing strategies and customer engagement[16]. - The company is focused on the strategic transformation of its generic drug CDMO business towards innovative drugs to create higher value[80]. Risk Management - The company has outlined various risks in its operations and has provided measures to mitigate these risks, as detailed in the management discussion and analysis section[6]. - The company has confirmed that there are no violations in decision-making procedures for external guarantees[12]. - The company faces risks related to talent retention and potential core technology leakage due to rapid business expansion and increased competition[153]. - The company has adopted a systematic approach to risk management, including strict inventory impairment policies to mitigate financial risks[159]. Acquisitions and Partnerships - The company acquired 100% equity of Yaoyuan Pharmaceutical, contributing to the increase in total assets[33]. - The company completed the acquisition of 100% equity in Yaoyuan Pharmaceutical, enhancing its formulation CDMO capabilities and expanding GMP production capacity[57]. - The company has established a new strategic partnership with a leading CRO to accelerate drug development timelines[18]. - The company acquired 100% equity of Zeda Fan Ke and Ya Yuan Pharmaceutical, enhancing its CDMO service capabilities[44]. Operational Efficiency - The company has established a comprehensive operational system covering human resources, R&D, production, quality control, and project management[149]. - The company has implemented an ERP resource management system to enhance operational efficiency through real-time data updates and dynamic monitoring[149]. - The company has established a stable management team and a robust governance structure to support its rapid growth and operational scale[156]. - The company has implemented a stock incentive system to maintain talent stability and support strategic goals[147]. Customer Base and Sales - The company employs a direct sales and distribution model, establishing stable partnerships with renowned distributors such as Thermo Fisher and Sigma-Aldrich, and actively expanding its global market presence[77]. - The company has a diverse customer base, including multinational pharmaceutical giants like Pfizer and Roche, as well as prestigious research institutions such as Harvard University and Oxford University[72]. - The top five customers contributed ¥23,275.85 million, accounting for 17.14% of total annual sales, with no related party sales included[180]. Inventory and Assets - The inventory balance increased, which is necessary to support future revenue growth, but it also impacted current accounting profits due to inventory impairment provisions[160]. - The company’s goodwill rose by 1,956.55% to ¥301,182,973.14, primarily due to the acquisition of pharmaceutical assets[193]. - The company’s fixed assets increased by 170.90% to ¥623,149,212.42, due to the completion of production facilities[193]. - Accounts receivable increased by 133.83% to ¥336,860,225.55, representing 9.36% of total assets, due to business expansion[191]. - Inventory surged by 158.72% to ¥910,876,848.98, making up 25.32% of total assets, driven by increased orders from downstream customers[192].

（2022 年 4 月） 上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|----------------------------------------|------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | 投资者关系活动类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | 其他（电话会议、论坛） | | 参与单位名称 | 2022 年 4 月 25 日 | | | | 信达证券、嘉实基金 | | | | 2022 年 4 月 28 日 | | | | 兴业证券、平安养老、开源证券、广发基金 | | | | 2022 年 4 月 29 日 | | | | | 天风证券、新华基金、信达证券、上投摩根、开源证券、富国基金 | | 时间 | 2022 年 4 月 25 日、 2 ...

（2022 年 6 月） 上海皓元医药股份有限公司 上海市浦东新区张衡路1999 号 3号楼 201203 上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|----------------------------------------------|--------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | 投资者关系活动类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | 其他（电话会议、论坛） | | 参与单位名称 | 2022 年 6 月 9 日 | | | | 长江证券、汇添富基金 | | | | 2022 年 6 月 10 日 | | | | 开源证券、工银瑞信基金 | | | | 2022 年 6 月 13 日 | | | | 开源证券、华商基金 | | | | ...